Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 241

1.

Cholinergic basal forebrain atrophy predicts amyloid burden in Alzheimer's disease.

Teipel S, Heinsen H, Amaro E Jr, Grinberg LT, Krause B, Grothe M; Alzheimer's Disease Neuroimaging Initiative.

Neurobiol Aging. 2014 Mar;35(3):482-91. doi: 10.1016/j.neurobiolaging.2013.09.029. Epub 2013 Oct 28.

2.

Association Between Smoking and Cholinergic Basal Forebrain Volume in Healthy Aging and Prodromal and Dementia Stages of Alzheimer's Disease.

Teipel S, Grothe MJ; Alzheimer’s Disease Neuroimaging Initiative.

J Alzheimers Dis. 2016 Apr 12;52(4):1443-51. doi: 10.3233/JAD-151100.

PMID:
27079707
3.

Atrophy of the cholinergic Basal forebrain over the adult age range and in early stages of Alzheimer's disease.

Grothe M, Heinsen H, Teipel SJ.

Biol Psychiatry. 2012 May 1;71(9):805-13. doi: 10.1016/j.biopsych.2011.06.019. Epub 2011 Aug 4.

4.

Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease.

Kerbler GM, Fripp J, Rowe CC, Villemagne VL, Salvado O, Rose S, Coulson EJ; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage Clin. 2014 Nov 27;7:105-13. doi: 10.1016/j.nicl.2014.11.015. eCollection 2015.

5.

Basal forebrain atrophy and cortical amyloid deposition in nondemented elderly subjects.

Grothe MJ, Ewers M, Krause B, Heinsen H, Teipel SJ; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2014 Oct;10(5 Suppl):S344-53. doi: 10.1016/j.jalz.2013.09.011. Epub 2014 Jan 10.

6.

Does posterior cingulate hypometabolism result from disconnection or local pathology across preclinical and clinical stages of Alzheimer's disease?

Teipel S, Grothe MJ; Alzheimer´s Disease Neuroimaging Initiative.

Eur J Nucl Med Mol Imaging. 2016 Mar;43(3):526-36. doi: 10.1007/s00259-015-3222-3. Epub 2015 Nov 10.

PMID:
26555082
7.

Parallel Atrophy of Cortex and Basal Forebrain Cholinergic System in Mild Cognitive Impairment.

Kilimann I, Hausner L, Fellgiebel A, Filippi M, Würdemann TJ, Heinsen H, Teipel SJ.

Cereb Cortex. 2017 Mar 1;27(3):1841-1848. doi: 10.1093/cercor/bhw019.

PMID:
26879092
8.

Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.

Tateno A, Sakayori T, Kawashima Y, Higuchi M, Suhara T, Mizumura S, Mintun MA, Skovronsky DM, Honjo K, Ishihara K, Kumita S, Suzuki H, Okubo Y.

Int J Geriatr Psychiatry. 2015 May;30(5):505-13. doi: 10.1002/gps.4173. Epub 2014 Jul 7.

PMID:
25043833
9.

Basal Forebrain and Hippocampus as Predictors of Conversion to Alzheimer's Disease in Patients with Mild Cognitive Impairment - A Multicenter DTI and Volumetry Study.

Brueggen K, Dyrba M, Barkhof F, Hausner L, Filippi M, Nestor PJ, Hauenstein K, Klöppel S, Grothe MJ, Kasper E, Teipel SJ.

J Alzheimers Dis. 2015;48(1):197-204. doi: 10.3233/JAD-150063.

PMID:
26401940
10.

Distinct pattern of hypometabolism and atrophy in preclinical and predementia Alzheimer's disease.

Kljajevic V, Grothe MJ, Ewers M, Teipel S; Alzheimer's Disease Neuroimaging Initiative.

Neurobiol Aging. 2014 Sep;35(9):1973-81. doi: 10.1016/j.neurobiolaging.2014.04.006. Epub 2014 Apr 13.

PMID:
24811241
11.

Relationship of Hippocampal Volume to Amyloid Burden across Diagnostic Stages of Alzheimer's Disease.

Trzepacz PT, Hochstetler H, Yu P, Castelluccio P, Witte MM, Dell'Agnello G, Degenhardt EK; Alzheimer''s Disease Neuroimaging Initiative.

Dement Geriatr Cogn Disord. 2016;41(1-2):68-79. doi: 10.1159/000441351. Epub 2015 Dec 2.

PMID:
26625159
12.

Discriminative Power of Arterial Spin Labeling Magnetic Resonance Imaging and 18F-Fluorodeoxyglucose Positron Emission Tomography Changes for Amyloid-β-Positive Subjects in the Alzheimer's Disease Continuum.

Tosun D, Schuff N, Jagust W, Weiner MW; Alzheimer''s Disease Neuroimaging Initiative.

Neurodegener Dis. 2016;16(1-2):87-94. doi: 10.1159/000439257. Epub 2015 Nov 12.

PMID:
26560336
13.

Subregional basal forebrain atrophy in Alzheimer's disease: a multicenter study.

Kilimann I, Grothe M, Heinsen H, Alho EJ, Grinberg L, Amaro E Jr, Dos Santos GA, da Silva RE, Mitchell AJ, Frisoni GB, Bokde AL, Fellgiebel A, Filippi M, Hampel H, Klöppel S, Teipel SJ.

J Alzheimers Dis. 2014;40(3):687-700. doi: 10.3233/JAD-132345.

14.

Association of brain amyloid-β with cerebral perfusion and structure in Alzheimer's disease and mild cognitive impairment.

Mattsson N, Tosun D, Insel PS, Simonson A, Jack CR Jr, Beckett LA, Donohue M, Jagust W, Schuff N, Weiner MW; Alzheimer's Disease Neuroimaging Initiative.

Brain. 2014 May;137(Pt 5):1550-61. doi: 10.1093/brain/awu043. Epub 2014 Mar 12.

15.

Imaging characteristic of dual-phase (18)F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer's disease and mild cognitive impairment.

Lin KJ, Hsiao IT, Hsu JL, Huang CC, Huang KL, Hsieh CJ, Wey SP, Yen TC.

Eur J Nucl Med Mol Imaging. 2016 Jul;43(7):1304-14. doi: 10.1007/s00259-016-3359-8. Epub 2016 Mar 22.

PMID:
27003417
16.

Patterns of Cortical and Subcortical Amyloid Burden across Stages of Preclinical Alzheimer's Disease.

Edmonds EC, Bangen KJ, Delano-Wood L, Nation DA, Furst AJ, Salmon DP, Bondi MW; Alzheimer’s Disease Neuroimaging Initiative.

J Int Neuropsychol Soc. 2016 Nov;22(10):978-990.

17.

Hippocampal and cortical atrophy in amyloid-negative mild cognitive impairments: comparison with amyloid-positive mild cognitive impairment.

Ye BS, Seo SW, Kim CH, Jeon S, Kim GH, Noh Y, Cho H, Yoon CW, Kim HJ, Jang EY, Lee J, Kim JH, Chin J, Lee JM, Kim JH, Seong JK, Kim CH, Choe YS, Lee KH, Na DL.

Neurobiol Aging. 2014 Feb;35(2):291-300. doi: 10.1016/j.neurobiolaging.2013.08.017. Epub 2013 Sep 27.

PMID:
24080178
18.

Amyloid Beta-Weighted Cortical Thickness: A New Imaging Biomarker in Alzheimer's Disease.

Kim CM, Hwang J, Lee JM, Roh JH, Lee JH, Koh JY; Alzheimer’s Disease Neuroimaging Initiative (ADNI).

Curr Alzheimer Res. 2015;12(6):563-71.

PMID:
26027813
19.

Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease.

Jack CR Jr, Wiste HJ, Vemuri P, Weigand SD, Senjem ML, Zeng G, Bernstein MA, Gunter JL, Pankratz VS, Aisen PS, Weiner MW, Petersen RC, Shaw LM, Trojanowski JQ, Knopman DS; Alzheimer's Disease Neuroimaging Initiative.

Brain. 2010 Nov;133(11):3336-48. doi: 10.1093/brain/awq277. Epub 2010 Oct 8.

20.

Patients with Amyloid-Negative Mild Cognitive Impairment have Cortical Hypometabolism but the Hippocampus is Preserved.

Hanseeuw B, Dricot L, Lhommel R, Quenon L, Ivanoiu A.

J Alzheimers Dis. 2016 May 23;53(2):651-60. doi: 10.3233/JAD-160204.

PMID:
27232217

Supplemental Content

Support Center